PPARG inverse agonists and uses thereof

By providing compounds with specific structures to regulate PPARG activity, the problem of limited treatment options for urothelial cancer is solved, and effective treatment of PPARG-related diseases is achieved, especially the therapeutic effect of urothelial cancer is improved.

CN118984823APending Publication Date: 2024-11-19FLARE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033175.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-08
Filing Date
2023-03-03
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing treatments for urothelial carcinoma are limited, especially for non-muscular invasive urothelial carcinoma associated with PPARG overexpression, with limited treatment options and poor survival rates.

Method used

A compound with a specific structure and a pharmaceutically acceptable salt are provided for regulating PPARG activity as an agonist, inverse agonist, for the treatment of diseases associated with PPARG, including cancers such as urothelial carcinoma.

Benefits of technology

These compounds can effectively regulate PPARG activity, overcome the functional activation state caused by changes in PPARG activity, provide a higher inhibitory effect of NCOR1 recruitment, and are used to treat urothelial carcinoma and other conditions related to PPARG function, and improve the treatment of urine Selectivity and effects of road epithelial carcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984823A_ABST
    Figure CN118984823A_ABST
Patent Text Reader

Abstract

Compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof are provided that are useful for treatment of various conditions associated with PPARG: # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 317,740, filed on March 8, 2022, the entire contents of which are incorporated herein by reference. Background Art

[0003] PPARγ (PPARG) is a type II ligand-dependent nuclear hormone receptor (belonging to the PPAR nuclear receptor subfamily) that functions as an obligate heterodimer with the retinoid X receptor (RXR). PPARG is primarily expressed in adipose tissue, colon, macrophages, and the luminal layer of the urothelium. PPARG is considered a master regulator of adipogenesis, and its functions are to regulate adipocyte differentiation, fatty acid storage, and glucose metabolism. PPARG has also been shown to play an important role in the metabolism and inflammation of macrophages, where it is induced by IL4 and controls glutamine metabolism. In the normal urothelium, PPARG is essential for its homeostasis and regeneration.

[0004] The role of PPARG in cancer was initially inferred from genomic studies that identified PAX8-PPARG chromosomal rearrangements in follicular thyroid carcinoma. More recently, PPARG has been found to be overexpressed and genetically altered in the luminal subtype of urothelial carcinoma. This is consistent with reports that long-term use of PPARG agonists is associated with an increased incidence of urothelial carcinoma. Most urothelial cancers are urothelial adenocarcinomas, which are classified as non-muscle-invasive urothelial carcinoma (NMIUC, 70%), muscle-invasive urothelial carcinoma (MIUC, 25%), or metastatic urothelial carcinoma (MUC, 5%). MIUC is usually diagnosed de novo but may also result from eventual progression in 10% to 20% of NMIUC cases. MIUC is a heterogeneous, invasive disease with a five-year survival rate of 60% for patients with localized disease and less than 10% for patients with distant metastases. The molecular understanding of NMIUC and MIUC has improved significantly, including the association between molecular subtypes and urothelial differentiation. Several molecular classifications of MIUC have been proposed, with an activated PPARG signature being prominent in the luminal subtype. First-line treatment is chemotherapy, with several options available in cases where chemotherapy is not indicated or as second-line therapy, but treatment options are limited and overall survival is poor.

[0005] There is a need to develop effective PPARG modulators for the treatment of cancers such as NMIUC, MIUC and MUC, and related disorders. Summary of the invention

[0006] Provided herein are compounds having Formula I:

[0007]

[0008] and pharmaceutically acceptable salts and compositions thereof, wherein R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , W, X, Y, Z, q and r are as described herein. In one aspect, the disclosed compounds of Formula I and their pharmaceutically acceptable salts modulate PPARG (e.g., as agonists, such as inverse agonists) and can be used in a variety of therapeutic applications, such as treating cancer. Therefore, their use in treating diseases responsive to inhibition of PPARG is also included.

[0009] Also included are pharmaceutical compositions comprising the disclosed compounds of Formula I and pharmaceutically acceptable salts of the compounds, and methods for their preparation. DETAILED DESCRIPTION

[0010] 1. General description of the compound

[0011] In a first embodiment, provided herein is a compound of Formula I:

[0012]

[0013] or a pharmaceutically acceptable salt thereof, wherein:

[0014] X, Y and Z are each independently selected from N and -CR 4 ;

[0015] W is selected from O and CR a R b ;

[0016] R 1 is selected from hydrogen, halogen, (C1-C4)alkyl and hydroxy;

[0017] R 2 Selected from halogen, -SR a 、-SOR a 、-SO2R a 、-OR a and -SO(=NR a )R b ;

[0018] R 3 is selected from cyano and nitro;

[0019] R 4 is selected from hydrogen, halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy and hydroxy;

[0020] R 5 is selected from phenyl, heterocyclyl and heteroaryl, each of which is optionally substituted by 1 to 3 selected from R 8 The group substitution;

[0021] R 6 and R 7 Each is independently selected from halogen, (C1-C4) alkyl, (C1-C4) alkoxy, halo (C1-C4) alkyl, halo (C1-C4) alkoxy, cyano, oxo, -(C1-C4) alkyl, OR a 、-(C1-C4)alkylC(O)R a 、-(C1-C4)alkylC(O)OR a 、-C(O)NR a R b 、-(C1-C4)alkylC(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-NR a R b 、-(C1-C4)alkylNR a R b 、-C(O)NR a SO3H, -NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(S)OR b 、-NR c C(O)N a R b 、-NR c C(S)NR a R b 、-NR c S(O)2NR a R b 、-C(S)R a 、-S(O)2R a 、-S(O)R a 、-C(S)OR a 、-C(S)NR a R b 、-NR a C(S)R b 、-SR a , phenyl, heterocyclic group and heteroaryl, wherein the phenyl, heterocyclic group and heteroaryl are each optionally and independently substituted by 1 to 3 selected from R 9 The group substitution;

[0022] R 8 and R 9 Each is independently selected from halogen, (C1-C4) alkyl, halo (C1-C4) alkyl, (C1-C4) alkoxy, halo (C1-C4) alkoxy, nitro, oxo, cyano, -(C1-C4) alkyl, OR d 、-(C1-C4)alkylC(O)R d 、-(C1-C4)alkylC(O)OR d 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、-C(O)R d 、-C(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d SO3H, -NR d C(O)R e 、-NR d C(O)OR e 、-NR d C(S)OR e 、-NR f C(O)N d R e 、-NR f C(S)NR d R e 、-NR f S(O)2NR d R e 、-C(S)R d 、-S(O)2R d 、-S(O)R d 、-C(S)OR d 、-C(S)NR d R e 、-NR d C(S)R e and-SR d ;

[0023] R a , R b , R c , R d and R e are each independently selected from hydrogen, (C1-C4)alkyl and halo(C1-C4)alkyl; and

[0024] q and r are each independently 0 or 1.

[0025] 2. definition

[0026] When used to describe a chemical group that may have multiple points of attachment, the hyphen (-) indicates the point of attachment of the group to the variable that defines it. For example, -NR b C(O)OR c and-NR b C(S)OR c It is intended that the point of attachment of the group occurs on the nitrogen atom.

[0027] The terms "halo" and "halogen" refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br) and iodine (iodo, -I).

[0028] The term "alkyl" when used alone or as part of a larger moiety, such as "haloalkyl," etc., refers to a saturated straight or branched chain monovalent hydrocarbon radical.

[0029] "Alkoxy" refers to an alkyl group connected through an oxygen linking atom, represented by -O-alkyl. For example, "(C1-C4)alkoxy" includes methoxy, ethoxy, propoxy and butoxy.

[0030] The term "haloalkyl" includes mono-, poly- and perhaloalkyl groups wherein the halogen is independently selected from fluorine, chlorine, bromine and iodine.

[0031] "Haloalkoxy" is a haloalkyl group attached to another moiety through an oxygen atom, for example, -OCHF2 or -OCF3.

[0032] The term oxo refers to the group =0.

[0033] The term "heteroaryl", used alone or as part of a larger moiety, refers to a 5 to 12 membered aromatic group containing 1 to 4 heteroatoms selected from N, O and S. The heteroaryl group can be monocyclic or bicyclic. Monocyclic heteroaryl includes, for example, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, triazinyl, tetrazinyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc. Bicyclic heteroaryl includes groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings. Non-limiting examples include indolyl, imidazopyridinyl, benzoxazolyl, benzoxadiazole, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, quinazolinyl, quinoxalinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrazolopyridinyl, thienopyridinyl, thienopyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. It should be understood that when specified, the optional substituents on the heteroaryl can be present in any substitutable position, and include, for example, the position at which the heteroaryl is attached.

[0034] The term "heterocyclic radical" refers to a 5 to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O and S. It can be a monocyclic, a bicyclic (e.g., a bridged, fused or spirocyclic bicyclic) or a tricyclic. The heterocyclic radical ring can be connected to its side group at any heteroatom or carbon atom producing a stable structure. The example of such saturated or partially unsaturated heterocyclic groups includes but is not limited to tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, pyrrolidinyl, pyridone, pyrrolidinone, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridyl, tetrahydropyridyl, dihydropyrimidinyl, oxetanyl, azetidinyl and tetrahydropyrimidinyl. Heterocyclic radical can be a monocyclic or bicyclic ring. The term "heterocyclyl" also includes, for example, an unsaturated heterocyclic group fused to another unsaturated heterocyclic group or an aryl or heteroaromatic ring, such as tetrahydronaphthyridine, indolinone, dihydropyrrole triazole, imidazopyrimidine, quinolone, dioxaspirodecane. It should also be understood that, when specified, the optional substituents on the heterocyclic group can be present at any substitutable position, and include, for example, the position where the heterocyclic group is attached (e.g., in the case of an optionally substituted heterocyclic group or an optionally substituted heterocyclic group).

[0035] The term "spirocycle" refers to two rings that share one ring atom (eg, carbon).

[0036] The term "fused" refers to two rings that share two adjacent ring atoms with each other.

[0037] The term "bridged" refers to two rings that share three ring atoms with each other.

[0038] The disclosed compounds may exist in one or more tautomeric forms, such as those below, and are included herein.

[0039]

[0040] The terms "subject" and "patient" are used interchangeably and refer to mammals in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.). Typically, the subject is a human in need of treatment.

[0041] The terms "inhibit," "inhibition" or "inhibiting" include a decrease in the baseline activity of a biological activity or process.

[0042] As used herein, the term "treatment (treatment, treat and treating)" refers to reversing, alleviating, delaying the onset of a disease or disorder as described herein or one or more of its symptoms or inhibiting its progression. In some aspects, treatment can be administered after the occurrence of one or more symptoms, i.e., therapeutic treatment. In other aspects, treatment can be performed in the absence of symptoms. For example, susceptible individuals can be treated before the onset of symptoms (e.g., according to a history of symptoms and / or according to exposure to a specific organism, or other predisposing factors), i.e., preventive treatment. Treatment can also be continued after the symptoms have been eliminated, for example, to delay its recurrence.

[0043] The term "pharmaceutically acceptable carrier" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound formulated therewith. Pharmaceutically acceptable carriers, adjuvants, or vehicles that can be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.

[0044] For use in medicine, the salts of the compounds described herein refer to non-toxic "pharmaceutically acceptable salts". Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic / anionic or basic / cationic salts. Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include, for example, salts of inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, and sulfuric acid) and salts of organic acids (e.g., acetic acid, benzenesulfonic acid, benzoic acid, methanesulfonic acid, and p-toluenesulfonic acid). The compounds of the present teachings having acidic groups such as carboxylic acids can form pharmaceutically acceptable salts with one or more pharmaceutically acceptable bases. Suitable pharmaceutically acceptable basic salts include, for example, ammonium salts, alkali metal salts (e.g., sodium and potassium salts), and alkaline earth metal salts (e.g., magnesium and calcium salts). Compounds having quaternary ammonium groups also contain counter anions, such as chloride, bromide, iodide, acetate, perchlorate, and the like. Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, benzoates, and salts with amino acids such as glutamic acid.

[0045] The term "effective amount" or "therapeutically effective amount" refers to an amount of a compound described herein that will elicit a desired or beneficial biological or medical response in a subject, such as a dosage between 0.01-100 mg / kg body weight / day.

[0046] 3. Compound

[0047] In a second embodiment, R1 in the compound of Formula I or a pharmaceutically acceptable salt thereof is hydrogen, wherein the remaining variables are as described above for Formula I.

[0048] In a third embodiment, X, Y and Z in the compound of Formula I or a pharmaceutically acceptable salt thereof are each -CR 4 , wherein the remaining variables are as described above for Formula I or the second embodiment.

[0049] In a fourth embodiment, the compound of Formula I or a pharmaceutically acceptable salt thereof wherein R 4 is selected from hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl and (C1-C4)alkoxy, wherein the remaining variables are as described above for Formula I or the second or third embodiment. Alternatively, as part of a fourth embodiment, R in the compound of Formula I or a pharmaceutically acceptable salt thereof is 4 is hydrogen, wherein the remaining variables are as described above for Formula I or the second or third embodiment.

[0050] In a fifth embodiment, R3 in the compound of Formula I, or a pharmaceutically acceptable salt thereof, is cyano, wherein the remaining variables are as described above for Formula I or the second, third or fourth embodiment.

[0051] In a sixth embodiment, R2 in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from halogen, -SR a 、-SOR a 、-SO2R a and -SO(=NR a )R b , wherein the remaining variables are as described above for Formula I or the second, third, fourth or fifth embodiment. Alternatively, as part of a sixth embodiment, the compound of Formula I or a pharmaceutically acceptable salt thereof wherein R 2 SO2R a , wherein the remaining variables are as described above for Formula I or the second, third, fourth or fifth embodiment. In another alternative, as part of the sixth embodiment, the compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from chlorine and -SO2Me, wherein the remainder of the variables are as described above for Formula I or the second, third, fourth or fifth embodiment.

[0052] In a seventh embodiment, R6 in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from halogen, oxo, cyano, (C1-C4) alkyl, halo (C1-C4) alkyl, (C1-C4) alkoxy, halo (C1-C4) alkoxy, -(C1-C4) alkyl, OR d 、-(C1-C4)alkylC(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、-C(O)R d 、-C(O)OR d 、-S(O)2R d 、-S(O)R d and-SR d , wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth or sixth embodiment.

[0053] In an eighth embodiment, r in the compound of Formula I or a pharmaceutically acceptable salt thereof is 0, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth or seventh embodiment.

[0054] In a ninth embodiment, the compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein q is 1, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh or eighth embodiment.

[0055] In the tenth embodiment, R7 in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from halogen, oxo, cyano, (C1-C4) alkyl, halo (C1-C4) alkyl, (C1-C4) alkoxy, halo (C1-C4) alkoxy, -(C1-C4) alkyl, OR d 、-(C1-C4)alkylC(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、-C(O)R d 、-C(O)OR d 、-S(O)2R d 、-S(O)R d and-SR d , wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment. Alternatively, as part of the tenth embodiment, R in the compound of Formula I or a pharmaceutically acceptable salt thereof is 7 is halogen, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment. In another alternative, as part of the tenth embodiment, R in the compound of Formula I or a pharmaceutically acceptable salt thereof is 7 is fluoro, wherein the remainder of the variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment.

[0056] In an eleventh embodiment, W in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from O and CH2, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment. Alternatively, as part of the eleventh embodiment, W in the compound of Formula I or a pharmaceutically acceptable salt thereof is O, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment.

[0057] In a twelfth embodiment, R5 in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from phenyl and monocyclic heteroaryl, each of which is optionally substituted by 1 to 3 selected from R 8wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiment. Alternatively, as part of the twelfth embodiment, R in the compound of Formula I or a pharmaceutically acceptable salt thereof is 5 is selected from phenyl and pyrazolyl, each of which is optionally substituted by 1 to 3 selected from R 8 wherein the remainder of the variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiment.

[0058] In a thirteenth embodiment, the compound of Formula I or a pharmaceutically acceptable salt thereof wherein R 8 is selected from halogen, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, -(C1-C4)alkyl, OR d 、-(C1-C4)alkylC(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)MR d R e 、-(C1-C4)alkylC(O)MR d R e 、-C(O)R d 、-C(O)OR d 、-S(O)2R d 、-S(O)R d and-SR d , wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh or twelfth embodiment. Alternatively, as part of the thirteenth embodiment, R8 in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from halogen and (C1-C4) alkyl, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh or twelfth embodiment. In another alternative, as part of the thirteenth embodiment, R8 in the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from halogen and (C1-C4) alkyl. 8 is selected from halogen and (C1-C4) alkyl, wherein the remaining variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh or twelfth embodiment. In another alternative, as part of the thirteenth embodiment, R in the compound of Formula I or a pharmaceutically acceptable salt thereof is 8is selected from chloro and methyl, wherein the remainder of the variables are as described above for Formula I or the second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh or twelfth embodiment.

[0059] Compounds having Formula I are further disclosed in the Examples and are encompassed by the present invention, including pharmaceutically acceptable salts and neutral forms thereof.

[0060] 4. Uses, preparations and administration

[0061] The compounds and compositions described herein are generally useful for modulating the activity of PPARG. In some aspects, the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions described herein inhibit PPARG activity. In some aspects, the compounds and pharmaceutically acceptable salts disclosed herein are agonists of PPARG. In some aspects, the compounds and pharmaceutically acceptable salts disclosed herein are agonists of PPARG. In some aspects, the compounds and pharmaceutically acceptable salts disclosed herein are inverse agonists of PPARG. In one aspect, an "inverse agonist" refers to an agent that binds to the same receptor binding site (e.g., a nuclear receptor such as a binding site of PPARG) as an agonist and not only antagonizes the action of the agonist but also exerts an opposite effect by inhibiting spontaneous receptor signaling (when present).

[0062] In some aspects, the compounds and pharmaceutically acceptable salts disclosed herein overcome the activation state of PPARG function caused by changes in PPARG activity (mutation, amplification or overexpression) or by RXRA activating mutations. In some aspects, the compounds and pharmaceutically acceptable salts disclosed herein increase the inhibitory state (NCOR1 recruitment) to a higher degree than previously disclosed PPARG modulators (e.g., existing inverse agonists). Such results even occur in a mutant environment. For example, see the table in the Examples section that qualitatively evaluates NCOR1 recruitment and PPARG target gene inhibition in HT1197.

[0063] In some aspects, the compounds and pharmaceutical compositions described herein can be used to treat disorders associated with PPARG function. Thus, provided herein are methods for treating disorders associated with PPARG function, comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or a pharmaceutically acceptable salt thereof.

[0064] Also provided is the use of a compound described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the disclosed compound or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disorder related to PPARG function. Also provided is a compound described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the disclosed compound or a pharmaceutically acceptable salt thereof, for treating a disorder related to PPARG.

[0065] In one aspect, the disorder associated with PPARG is cancer. In some aspects, cancer is associated with upregulated peroxisome proliferator-activated receptor (PPAR) signaling pathway. In some aspects, the upregulated PPAR signaling pathway is associated with increased expression of one or more genes selected from the group consisting of Uroplakin 1A (UPK1A), Uroplakin IB (UPK1B), Uroplakin (UPK2), Keratin 20 (KRT20), GATA binding protein 3 (GATA3), Nuclear receptor corepressor 1 (NCOR1), Nuclear receptor corepressor 2 (NCOR2), Fatty acid binding protein 4 (FABP4), Forkhead Box A1 (FOXA1), CD36 molecule (CD36), Acyl-CoA oxidase 1 (ACOX1), 3-hydroxy-3-methylglutaryl-CoA synthetase 2 (HMGCS2), Acyl-CoA synthetase long-chain family member 5 (ACSL5), Arachidonic acid 5-lipoxygenase (ALOX5), Acyl-CoA synthetase long-chain family member 1 (ACSL1), and Angiopoietin-like 4 (ANGPTL4).

[0066] In some aspects, the cancer treated by the compounds described herein, their pharmaceutically acceptable salts, and pharmaceutical compositions is selected from breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, kidney cancer, bladder cancer, testicular cancer, urothelial cancer (e.g., non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, metastatic urothelial cancer), skin cancer, melanoma, colon cancer, kidney cancer, brain cancer, and hematopoietic cancer (e.g., lymphoma, multiple myeloma, and leukemia). In one aspect, the cancer treated by the compounds described herein, their pharmaceutically acceptable salts, and pharmaceutical compositions is urothelial cancer, e.g., non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, and metastatic urothelial cancer.

[0067] Other uses besides cancer are contemplated and include, for example, metabolic diseases (e.g., osteoporosis, spondylitis, arthropathy, obesity, type I and type II diabetes), lipid metabolism disorders, pancreatitis, glucose metabolism disorders, diabetic neuropathy, diabetic complications, hyperuricemia, osteoporosis, spondylitis, arthropathy, inflammatory diseases (e.g., inflammatory skin diseases such as psoriasis, atopic dermatitis, eczema, acne vulgaris, other dermatitis and pruritus), pulmonary diseases (e.g., asthma and chronic obstructive pulmonary disease), autoimmune diseases, neurodegenerative diseases (e.g., multiple sclerosis, Alzheimer's disease and Parkinson's disease), cardiovascular diseases (e.g., selected from atherosclerosis, venous and arterial occlusive diseases), restenosis after invasive surgery, cardiomyopathy, myocardial fibrosis, congestive heart failure, angiogenesis and neovascularization in neoplastic diseases, and kidney diseases.

[0068] In some aspects, pharmaceutical compositions as described herein are formulated for application to patients in need of such compositions. Pharmaceutical compositions as described herein can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implantable kit. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the composition is administered orally, intraperitoneally or intravenously. The sterile injection form of pharmaceutical compositions as described herein can be an aqueous or oily suspension. These suspensions can be prepared using suitable dispersants or wetting agents and suspending agents according to technology known in the art.

[0069] In some aspects, the pharmaceutical composition is administered orally.

[0070] The specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound employed, age, body weight, general physical health, sex, diet, time of administration, rate of excretion, co-administration, and the judgment of the treating physician and the severity of the specific disease being treated. The amount of the compound described herein in the composition will also depend on the specific compound in the pharmaceutical composition.

[0071] Example

[0072] Chemical synthesis

[0073] The following representative examples are intended to help illustrate the present disclosure and are not intended, and should not be construed, to limit the scope of the invention.

[0074] Starting Materials

[0075]

[0076] 1-(2-Amino-4-chloro-6-fluorophenyl)ethan-1-one:To a solution of 3-chloro-5-fluoroaniline (20.0 g, 137 mmol, 1.0 equiv) in p-xylene (40.0 mL) was added BCl (182.7 mL, 1 M, 1.33 equiv) at 0-5 ° C over 2 hours, then the mixture was warmed to 22 ° C for 0.5 hours, stirred at 20-22 ° C for 10 minutes, and then acetonitrile (57.8 mL, 1.1 mol, 8.0 equiv) was added dropwise to the mixture at 25 ° C over 20 minutes. The mixture was stirred at 20-22 ° C for 10 minutes, and then p-xylene (44.8 mL) was added to the mixture. Then AlCl (10.3 g, 76.9 mmol, 4.2 mL, 0.56 equiv) was added to the mixture at one time. The mixture was stirred at 22 ° C for 1 hour, and then at 75-77 ° C for 12 hours. HCl (4N, 200 mL) was added and the reaction mixture was stirred at 80°C for 4 hours. The mixture was poured into water (800 mL) and extracted with ethyl acetate (1.500 L). The organic phase was washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (50:1 to 20:1 petroleum ether: ethyl acetate) to give the title compound (4.6 g, 18% yield) as a light yellow solid. LCMS [M+1] = 188.0 / 190.0. 1 H NMR (chloroform-d, 400 MHz) δ 6.31-6.52 (m, 4H), 2.58 (d, J=8.4 Hz, 3H).

[0077]

[0078] 5 -Cyano-2-(methylthio)benzoyl chloride

[0079] Step 1, 2-chloro-5-cyano-benzoic acid methyl ester: To a solution of 2-chloro-5-cyano-benzoic acid (10 g, 55.0 mmol, 1.0 equiv) was added SOCl2 (82.0 g, 689.2 mmol, 50 mL, 12.5 equiv). The reaction mixture was stirred at 80 ° C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was dissolved in THF (50 mL) and added to MeOH (50 mL). The residue was diluted with saturated NaHCO3 aqueous solution (100 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the title compound (9 g, 84% yield) as a white solid. 1H NMR (400MHz, CDCl3) δ 8.15 (d, J=2.0Hz, 1H), 7.70 (dd, J=2.0, 8.4Hz, 1H), 7.60 (d, J=8.4Hz, 1H), 3.98 (s, 3H).

[0080] Step 2, 5-cyano-2-methylsulfanyl-benzoic acid: To a solution of NaSMe (35.83 g, 511 mmol, 2.5 equiv) in DMF (400 mL) was added dropwise a solution of 2-chloro-5-cyano-benzoic acid methyl ester (40 g, 205 mmol, 1.0 equiv) in DMF (400 mL) at 0°C. The mixture was then stirred at 0°C for 3 hours. The pH of the reaction mixture was adjusted to pH = 1 with HCl (1 M). The mixture was filtered and the filter cake was dried under vacuum to give the title compound (30 g, 76% yield) as a white solid. LCMS [M-1] = 192.1. 1 H NMR (400MHz, DMSO-d6) δ13.53 (br s, 1H), 8.21 (d, J=2.0Hz, 1H), 7.92 (dd, J=2.0, 8.4Hz, 1H), 7.51 (d, J=8.6Hz, 1H), 2.46 (s, 3H).

[0081] Step 3, 5-cyano-2- (First Thio)benzoyl chloride: A solution of 5-cyano-2-(methylthio)benzoic acid (4.2 g, 22.0 mmol, 1.0 equiv) in SOCl2 (56 mL) was stirred at 80 °C for 1 hour. The mixture was concentrated under reduced pressure to give the title compound (4.6 g, 99% yield) as a yellow solid. The product was used without further purification.

[0082]

[0083] 4-Chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile

[0084] Scheme 1. 2-Chloro-5-cyanobenzoyl chloride:

[0085] A solution of 2-chloro-5-cyano-benzoic acid (2.5 g, 13.8 mmol) in SOCl2 (25 mL) was stirred at 80° C. for 1 h. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to give the title compound (2.8 g, crude) as a yellow solid, which was used directly in the next step.

[0086] Step 1. 1-(2-amino-4,6-difluorophenyl)ethanone:

[0087] To a solution of 3,5-difluoroaniline (8.9 g, 68.9 mmol, 1.0 equiv) in CH3CN (85 mL) was added BCl3 (1 M, 72.4 mL, 1.05 equiv) at 0°C. AlCl3 (10.1 g, 75.8 mmol, 4.1 mL, 1.1 equiv) was then added to the mixture in three portions, and the mixture was then stirred at 80°C for 16 hours. The mixture was cooled to 0°C, and then aqueous HCl (4 M, 80 mL) was added and the mixture was stirred at 80°C for 2 hours. The mixture was cooled to room temperature and extracted with EtOAc (2×150 mL). The combined organic layers were washed with saturated aqueous NaHCO3 (2×50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (8.0 g, 68% yield) as a light yellow solid. LCMS: for [M+H] + The calculated value of (C8H7F2NO) is m / z=172.0, and the measured value is m / z=172.1. 1 H NMR (400MHz, CDCl3), δ6.5 (br s, 2H), 6.0-6.2 (m, 2H), 2.6 (d, J=8.4Hz, 3H).

[0088] Step 2. N-(2-acetyl-3,5-difluorophenyl)-2-chloro-5-cyanobenzamide:

[0089] To a solution of 1-(2-amino-4,6-difluoro-phenyl)ethanone (2g, 11.7mmol, 1.0 equiv) in THF (20mL) was added NaH (467mg, 11.7mmol, 60% dispersion in oil, 1.0 equiv) at 0°C. The mixture was stirred for 30 minutes, and then a solution of 2-chloro-5-cyano-benzoyl chloride (2.6g, 12.8mmol, 1.1 equiv) in THF (10mL) was added dropwise. The mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched by adding saturated NH4Cl aqueous solution (15mL) at 15°C, diluted with water (20mL), and filtered. The filter cake was ground with EtOAc (20mL) and filtered to give the title compound (2.4g, 61% yield) as a white solid. LCMS: for [M+H] + (C 16 The calculated value of H9F3N2O2 is m / z=335.0, and the measured value is m / z=335.0. 1 H NMR (400MHz, DMSO-d6) δ11.2 (s, 1H), 8.1 (d, J=2.0Hz, 1H), 8.0 (dd, J=8.4, 2.2Hz, 1H), 7 .8 (d, J=8.4Hz, 1H), 7.5-7.5 (m, 1H), 7.3 (ddd, J=11.2, 8.8, 2.2Hz, 1H), 2.5-2.6 (m, 3H).

[0090] Step 3. 4-Chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile:

[0091] To a solution of N-(2-acetyl-3,5-difluoro-phenyl)-2-chloro-5-cyano-benzamide (2.5 g, 7.5 mmol, 1.0 equiv) in dioxane (40 mL) was added NaOH (3.0 g, 74.7 mmol, 10.0 equiv). The mixture was stirred at 110° C. for 1.5 hours. The pH of the reaction mixture was adjusted to 5 with aqueous HCl (1 M), then diluted with water (30 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (2×100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue, which was purified by preparative HPLC (column: Welch Xtimate C18 250×70 mm×10 um; mobile phase: 15-45% acetonitrile in water (10 mM NH4HCO3)). After concentration under reduced pressure, the title compound was obtained as a white solid (570 mg, 24% yield, 98% purity). LCMS: [M+H] + (C 16 The calculated value of H7ClF2N2O) requires m / z=317.0, and the measured value is m / z=317.0. 1 H NMR (400MHz, DMSO-d6) δ9.2-10.3 (m, 1H), 8.2 (d, J=2.0Hz, 1H), 8.0 (dd, J=8.4, 2.0Hz, 1H), 7.9 (d, J=8.4Hz, 1H), 7.0-7.2 (m, 2H), 6.1 (s, 1H).

[0092] Example 1

[0093]

[0094] 3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile

[0095] Step 1, 2-bromo-1-(4-chlorophenoxy)-5-fluoro-3-nitro-benzene:

[0096] At room temperature, N2, to a mixture of 2-bromo-1,5-difluoro-3-nitro-benzene (20.0 g, 84.0 mmol, 1.0 equivalent) and 4-chlorophenol (10.8 g, 84.0 mmol, 8.2 mL, 1.0 equivalent) in DMA (50 mL) was added CsCO (30.1 g, 92.4 mmol, 1.1 equivalent). The mixture was stirred at 65 ° C for 5 minutes. The reaction mixture was poured into ice water (500 mL) and stirred for 10 minutes. The aqueous phase was extracted with MTBE (3 x 350 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous NaSO, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (100% petroleum ether) to give a mixture of the title compound and 2-bromo-5-(4-chlorophenoxy)-1-fluoro-3-nitro-benzene (15.8 g, 45.6 mmol) as a yellow oil. The mixture of regioisomers was carried forward to the next step. 1 H NMR (400MHz, chloroform-d) δ8.01-7.93m, 1H), 7.77 (dd, J=2.4, 7.7Hz, 1H), 7.47 (t, J=1.9Hz, 1H), 7.43-7.42 (m, 1H), 7.44-7.40 (m, 3H), 7.35-7.27 (m, 2H), 7.08-6.99 (m, 4H), 6.93 (d, J=8.9Hz, 1H), 6.76 (dd, J=2.8, 9.0Hz, 1H).

[0097] Step 2, 2-bromo-3-(4-chlorophenoxy)-5-fluoro-aniline:

[0098] At room temperature under N2, to a solution of 2-bromo-5-(4-chlorophenoxy)-1-fluoro-3-nitro-benzene and 2-bromo-1-(4-chlorophenoxy)-5-fluoro-3-nitro-benzene mixture (14.8 g, 42.7 mmol, 1.0 equivalent) and iron (0) (11.9 g, 213.5 mmol, 5.0 equivalent) in ethanol (300 mL) was added once with NH4Cl (11.4 g, 213.5 mmol, 5.0 equivalent) in water (100 mL). The mixture was stirred at 80 ° C for 1 hour. The mixture was filtered through a diatomaceous earth pad and concentrated to 1 / 3 of the original volume under reduced pressure. The resulting solution was diluted with water (200 mL) and the aqueous phase was extracted with ethyl acetate (2×200 mL). The combined organic layer was washed with brine (2×20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (50:1 to 8:1 petroleum ether:ethyl acetate) to give the title compound as a yellow oil (7.0 g, 52% yield) and the undesired regioisomer 2-bromo-5-(4-chlorophenoxy)-3-fluoro-aniline (3.3 g, 24% yield) as a yellow oil. LCMS [M-1] = 314.1 / 315.9. 1 H NMR (400 MHz, CHLOROFORM-d) δ = 7.34-7.28 (m, 2H), 6.98-6.91 (m, 2H), 6.29 (dd, J = 2.5, 10.0 Hz, 1H), 6.03 (dd, J = 1.5, 2.5 Hz, 1H), 3.81 (br s, 2H).

[0099] Step 3, 1-(2-amino-6-(4-chlorophenoxy)-4-fluorophenyl)ethan-1-one:

[0100] To a mixture of 2-bromo-3-(4-chlorophenoxy)-5-fluoroaniline (1 g, 3.16 mmol, 1.0 equiv) and tributyl(1-ethoxyvinyl)stannane (586 μL, 1.74 mmol, 0.55 equiv) in toluene (10 mL) at room temperature under N2 was added Pd(PPh3)4 (365 mg, 316 μmol, 0.1 equiv). The mixture was stirred at 120°C for 4 hours under N2. The reaction was then cooled to room temperature and additional tributyl(1-ethoxyvinyl)stannane (586.4 μL, 1.74 mmol, 0.55 equiv) was added to the mixture. The mixture was stirred at 120°C for 12 hours. The reaction mixture was poured into aqueous KF solution (20 mL) and stirred for 2 hours. The aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give 3-(4-chlorophenoxy)-2-(1-ethoxyvinyl)-5-fluoroaniline (2.1 g, crude) as a brown oil, which was used in the next step without further purification.

[0101] A solution of 3-(4-chlorophenoxy)-2-(1-ethoxyvinyl)-5-fluoroaniline (970 mg, crude) in acetic acid (18 mL) and water (2 mL) was stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure and then treated with saturated NaHCO3 aqueous solution (70 mL) at 20°C. The aqueous layer was extracted with ethyl acetate (4×50 mL), and the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10:1 to 5:1 petroleum ether: ethyl acetate) to give the title compound (530 mg, 60% yield) as a yellow solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.40-7.33 (m, 2H), 7.04-6.99 (m, 2H), 6.52-6.11 (m, 2H), 6.08 (dd, J=2.4, 10.4 Hz, 1H), 5.76 (dd, J=2.4, 10.0 Hz, 1H), 2.59 (s, 3H).

[0102] Step 4, N-(2-acetyl-3-(4-chlorophenoxy)-5-fluorophenyl)-5-cyano-2-(methylthio)benzamide:

[0103] To a solution of 1-(2-amino-6-(4-chlorophenoxy)-4-fluorophenyl)ethan-1-one (200 mg, 715 μmol, 1.0 equiv) in isopropyl acetate (3 mL) was added 5-cyano-2-methylsulfanyl-benzoyl chloride (151 mg, 715 μmol, 1.0 equiv). The mixture was stirred at 80 °C for 16 h. The mixture was filtered and the filter cake was triturated with MTBE at room temperature for 1 h to give the title compound (200 mg, 62% yield) as a white solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 12.04 (s, 1H), 8.35 (dd, J = 2.4, 11.1 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.72 (dd, J = 1.8, 8.4 Hz, 1H), 7.45-7.39 (m, 3H), 7.04 (d, J = 8.8 Hz, 2H), 6.32 (dd, J = 2.4, 9.4 Hz, 1H), 2.69 (s, 3H), 2.54 (s, 3H).

[0104] Step 5, 3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzyl Nitrile:

[0105] To a solution of N-(2-acetyl-3-(4-chlorophenoxy)-5-fluorophenyl)-5-cyano-2-(methylthio)benzamide (200 mg, 440 μmol, 1.0 equiv) in 2-MeTHF (5 mL) was added LiOH (11.6 mg, 484 μmol, 1.1 equiv). The mixture was stirred at 95 °C for 14 hours. The pH of the solution was adjusted to pH = 1 with 1 M aqueous HCl. The solid precipitated from the solution was filtered off and triturated with acetonitrile at room temperature to give the title compound (200 mg, crude) as a white solid. 1 H NMR (400 MHz, methanol-d4) δ 7.94-7.86 (m, 2H), 7.65 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 8.8 Hz, 2H), 7.23 (br d, J = 8.8 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 6.79-6.69 (m, 2H), 2.60 (s, 3H).

[0106] Step 6, 3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl) Benzonitrile:

[0107] To a solution of 3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzonitrile (110 mg, 252 μmol, 1 eq) in acetone (2.8 mL), water (1.6 mL), THF (2 mL), and MeOH (2 mL) was added Oxone (774 mg, 1.26 mmol, 5 eq). The reaction mixture was stirred at 40 °C for 1.5 hours. The reaction mixture was quenched by adding a solution of Na2SO3 (800 mg) in water (10 mL) at room temperature. The aqueous layer was extracted with DCM (2×10 mL), and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 75 x 30 mm x 3 um; mobile phase: 1-50% acetonitrile in water (+ formic acid)) to give the title compound (49.1 mg, 42% yield) as a white solid. LCMS [M+1] = 469.0. 1 H NMR (400MHz, methanol-d4) δ8.37 (d, J=8.0Hz, 1H), 8.20 (br d, J=8.4Hz, 1H), 8.13 (s, 1H), 7.41 (d, J=8.8Hz, 2H), 7.06 (d, J=8.8Hz, 2H), 7.00 (br d, J=8.4Hz, 1H), 6.55 (br d, J=9.4Hz, 1H), 6.32-6.22m, 1H), 3.20 (s, 3H).

[0108] Example 2

[0109]

[0110] 4-Chloro-3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile

[0111] Step 1, N-(2-acetyl-3-(4-chlorophenoxy)-5-fluorophenyl)-2-chloro-5-cyanobenzamide:

[0112] To a solution of 1-(2-amino-6-(4-chlorophenoxy)-4-fluorophenyl)ethanone (100 mg, 358 μmol, 1.0 equiv) in isopropyl acetate (2.0 mL) was added 2-chloro-5-cyanobenzoyl chloride (78.6 mg, 393 μmol, 1.1 equiv). The reaction mixture was then stirred at 80 ° C for 12 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was triturated with acetonitrile to give the title compound (85 mg, 51% yield) as a yellow solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 11.89-11.79 (m, 1H), 8.33 (dd, J=2.4, 10.8 Hz, 1H), 7.93 (d, J=1.8 Hz, 1H), 7.73-7.71 (dd, J=2.0, 8.0 Hz, 1H), 7.64-7.62 (d, J=8.4 Hz, 1H), 7.44-7.41 (m, 2H), 7.06-7.03 (m, 2H), 6.36-6.33 (dd, J=2.4, 9.4 Hz, 1H), 2.68 (s, 3H).

[0113] Step 2, 4-chloro-3-(5-(4-chlorophenoxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile:

[0114] To a solution of N-(2-acetyl-3-(4-chlorophenoxy)-5-fluorophenyl)-2-chloro-5-cyanobenzamide (80 mg, 181 μmol, 1.0 equiv) in 2-MeTHF (1.0 mL) was added LiOH (8.64 mg, 361 μmol, 2.0 equiv). The reaction mixture was stirred at 80 °C under N2 for 16 hours. The pH of the reaction mixture was adjusted to pH = 3 with 1M HCl aqueous solution. The precipitate formed during the pH adjustment was collected by filtration. The crude product was triturated with acetonitrile to give the title compound (36 mg, 46% yield) as a white solid. LCMS [M+1] = 424.9. 1 H NMR (400 MHz, methanol-d4) δ 8.07-8.04 (m, 1H), 7.95-7.91 (m, 1H), 7.85-7.81 (m, 1H), 7.42-7.37 (m, 2H), 7.07-7.02 (m, 3H), 6.59-6.54 (m, 1H), 6.21 (br s, 1H).

[0115] Example 3

[0116]

[0117] 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinolin-2-yl)-4- (First (2-(2-(4 ...sulfonyl)benzonitrile))

[0118] Step 1, N-(2-acetyl-3,5-difluoro-phenyl)-5-cyano-2-methylsulfanyl-benzamide:

[0119] To a solution of 1-(2-amino-4,6-difluoro-phenyl)ethanone (400 mg, 2.34 mmol, 1.0 equiv) in isopropyl acetate (10 mL) was added 5-cyano-2-methylsulfanyl-benzoyl chloride (544 mg, 2.57 mmol, 1.1 equiv). The mixture was stirred at 80 °C for 16 hours. The reaction mixture was concentrated under reduced pressure to give the title compound (540 mg, 67% yield) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ 11.19 (s, 1H), 8.03 (m, 1H), 7.96 (m, 1H), 7.58-7.54 (m, 2H), 7.27 (m, 1H), 2.50 (s, 3H), 2.49 (s, 3H).

[0120] Step 2, 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfanyl-benzonitrile:

[0121] To a solution of N-(2-acetyl-3,5-difluoro-phenyl)-5-cyano-2-methylsulfanyl-benzamide (100 mg, 288.7 μmol, 1.0 equiv) in dioxane (2 mL) was added LiOH (6.9 mg, 289 μmol, 1.0 equiv). The mixture was stirred at 110 °C for 2 hours. The pH of the reaction mixture was adjusted to pH = 1 with 1M HCl aqueous solution. A precipitate was formed during the pH adjustment. The precipitate was filtered off and the filter cake was dried in vacuo to give the title compound (80 mg, 84% yield) as a yellow solid.

[0122] Step 3, 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinoline-2-yl) 4-(Methylthio)benzonitrile:

[0123] To a solution of 1-methyl-1H-pyrazol-4-ol (300 mg, 3.06 mmol, 1.0 equiv) in THF (2.0 mL) was added NaH (122 mg, 3.06 mmol, 1.0 equiv; 60% dispersion in oil). The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to give sodium 1-methylpyrazol-4-yl)oxide (368 mg, crude) as a white solid.

[0124] To a solution of 3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzonitrile (400 mg, 1.22 mmol, 1.0 equiv) in DMF (2.0 mL) was added sodium (1-methylpyrazol-4-yl)oxy (365.7 mg, 3.05 mmol, 2.5 equiv). The reaction mixture was stirred at 100 °C for 16 hours. The pH of the reaction mixture was adjusted to pH = 1 with 1M aqueous HCl. A precipitate formed during the pH adjustment, which was filtered off. The residue was purified by preparative HPLC (column: Phenomenex LunaC18 75 x 30 mm x 3 um; mobile phase: 10-40% acetonitrile in water (+ formic acid)) to give the title compound (65.0 mg, 13% yield) as a white solid. 1 H NMR (400MHz, methanol-d4) δ7.85 (dd, J=1.6, 8.4Hz, 1H), 7.81 (d, J=1.6Hz, 1H), 7.67 (s, 1H), 7.59 (d, J=8.4Hz, 1H), 7.44 (s, 1H), 6.90 (dd, J=1.8, 9.2Hz, 1H), 6.59 (dd, J=2.2, 10.8Hz, 1H), 6.25 (br s, 1H), 3.92 (s, 3H), 2.64-2.49 (m, 3H).

[0125] Step 4, 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinoline-2-yl) 4-(Methylsulfonyl)benzonitrile:

[0126] To a solution of 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylthio)benzonitrile (50 mg, 123 μmol, 1.0 equiv) in acetone (3.5 mL), water (2.0 mL), MeOH (2.5 mL) and THF (2.5 mL) was added Oxone (378 mg, 615 μmol, 5.0 equiv) and the reaction mixture solution was stirred at 30° C. for 3.5 hours. The reaction mixture was quenched by the addition of a saturated aqueous solution of Na2SO3 (9 mg) in water (1.0 mL) at 20° C. The aqueous layer was extracted with DCM (2×5 mL) and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was triturated with acetonitrile to give the title compound (14.3 mg, 26% yield) as a white solid. LCMS [M+1] = 439.1. 1HNMR (400MHz, methanol-d4) δ8.37 (d, J=8.2Hz, 1H), 8.20 (dd, J=1.4, 8.2Hz, 1H), 8.14 (d, J=1.2Hz, 1H), 7.68 (s, 1H), 7.46 (s, 1H), 6.87 (br d, J=7.0Hz, 1H), 6.60 (dd, J=1.8, 10.8Hz, 1H), 6.30 (br s, 1H), 3.92 (s, 3H), 3.24-3.18 (m, 3H).

[0127] Example 4

[0128]

[0129] 3-(7-chloro-5- (( 1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methyl (2-(2-(4 ...sulfonyl)benzonitrile))

[0130] The title compound was prepared in a similar manner to that described for 3-(7-fluoro-5-((1-methyl-1H-pyrazol-4-yl)oxy)-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile (Example 3) using N-(2-acetyl-5-chloro-3-fluorophenyl)-5-cyano-2-(methylthio)benzamide as starting material. LCMS [M+1] = 455.0. 1 HNMR (400MHz, methanol-d4) δ8.37 (d, J=8.2Hz, 1H), 8.20 (br d, J=8.2Hz, 1H), 8.15 (s, 1H), 7.68 (s, 1H), 7.45 (s, 1H), 7.20 (br s, 1H), 6.77 (s, 1H), 6.31 (br s, 1H), 3.93 (s, 3H), 3.21 (br s, 3H).

[0131] Example 5

[0132]

[0133] 4-Chloro-3-(5-((6-chloropyridin-3-yl)oxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile:

[0134] To a solution of 6-chloropyridin-3-ol (105 mg, 810.5 μmol, 1.0 equiv) in THF (2 mL) was added NaH (32.4 mg, 811 μmol, 1.0 equiv; 60% dispersion in oil) at 0° C., and the mixture solution was stirred for 2 hours at 20° C. The mixture was concentrated under reduced pressure to give sodium (6-chloro-3-pyridyl) oxide (123 mg, crude) as a white solid.

[0135] To a solution of 4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile (100 mg, 235 μmol, 1.0 equiv) in DMF (1.5 mL) was added sodium (6-chloro-3-pyridyl)oxy (61.4 mg, 474 μmol, 1.0 equiv). The mixture was stirred at 100 °C for 20 h. The mixture was quenched with saturated aqueous NH4Cl solution and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 75 x 30 mm x 3 um; mobile phase: 20-50% acetonitrile in water (+ formic acid)) to give the title compound (16.9 mg, 10% yield) as a yellow solid. LCMS [M+1] = 426.0. 1 H NMR (400MHz, DMSO-d6) δ12.15-12.08 (m, 1H), 8.22 (d, J=1.3Hz, 1H), 8.10-8.04 (m, 2H), 7.91(d, J=8.4Hz, 1H), 7.49-7.39m, 1H), 7.37-7.31(m, 1H), 7.28-7.17(m, 1H), 7.03(br d, J=9.7Hz, 1H), 5.96 (s, 1H).

[0136] Example 6

[0137]

[0138] 4-Chloro-3-(5-((4-chlorobenzyl)oxy)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile:

[0139] To a solution of 4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile (500 mg, 1.58 mmol, 1.0 equiv) in DMF (7 mL) was added (4-chlorophenyl)methanol (270 mg, 1.89 mmol, 1.2 equiv) and potassium tert-butoxide (532 mg, 4.74 mmol, 3.0 equiv). The mixture was stirred at 100 °C for 16 hours. The reaction mixture was diluted with water and ethyl acetate. The organic phase was separated, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (5:1 petroleum ether: ethyl acetate). The material was then purified by preparative HPLC (column: Phenomenex Luna C18 75x 30mmx 3um; mobile phase: 45-75% acetonitrile in water (+ formic acid)) to give the title compound (22.0 mg, 3.2% yield) as a white solid. LCMS [M+1] = 438.9. 1H NMR (400MHz, chloroform-d) δ9.96-9.15 (m, 1H), 7.97 (d, J=1.8Hz, 1H), 7.67-7.63 (m, 1H), 7.63-7.60 (m, 1H), 7. 49-7.44 (m, 4H), 7.40 (dd, J=1.8, 10.1Hz, 1H), 7.04 (s, 1H), 6.79 (dd, J=2.0, 10.0Hz, 1H), 5.30 (s, 2H).

[0140] Example 7

[0141]

[0142] 3-(5-(4-chlorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinolin-2-yl 0-4-(methylsulfonyl)benzonitrile

[0143] Step 1, 1-bromo-5-fluoro-2-iodo-3-nitrobenzene:

[0144] To a mixture of 2-bromo-4-fluoro-6-nitroaniline (2.0 g, 8.5 mmol, 1.0 eq.) in H2SO4 (25.8 mL, 50% purity) and H2O (6.5 mL) was added NaNO2 (769 mg, 11.2 mmol, 1.3 eq.) in portions at 0°C under N2. The mixture was stirred at 0°C for 30 minutes, then KI (3.7 g, 22.3 mmol, 2.6 eq.) was added to the mixture and the resulting mixture was stirred at 0°C for 40 minutes. The reaction mixture was poured into ice water (200 mL) and stirred for 10 minutes. The aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with saturated NaHCO3 aqueous solution (200 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (100:1 to 20:1 petroleum ether:ethyl acetate) to give the title compound (2.5 g, 50% yield) as a yellow solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.66 (dd, J = 2.8, 7.4 Hz, 1H), 7.36 (dd, J = 2.8, 7.3 Hz, 1H).

[0145] Step 2, 3-bromo-5-fluoro-2-iodoaniline:

[0146] To a solution of 1-bromo-5-fluoro-2-iodo-3-nitro-benzene (2.5 g, 6.5 mmol, 90.0% purity, 1.0 equiv) and NH4Cl (1.74 g, 32.52 mmol, 5.0 equiv) in ethanol (30 mL) and H2O (10 mL) was added Fe (1.8 g, 32.5 mmol, 5.0 equiv) at 20°C under N2. The mixture was stirred at 80°C for 2 hours. The mixture was filtered through a celite pad and the filtrate was concentrated in vacuo. The residue was poured into ice water (200 mL). The aqueous phase was extracted with ethyl acetate (2×150 mL). The combined organic layers were washed with brine (2×20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50:1 to 10: petroleum ether: ethyl acetate) to give the title compound (2.0 g, 97% yield) as a light yellow solid. LCMS [M+1] = 315.8. 1 H NMR (400 MHz, CHLOROFORM-d) δ 6.84 (dd, J=2.6, 8.2 Hz, 1H), 6.41 (dd, J=2.6, 10.2 Hz, 1H), 4.48 (br s, 2H).

[0147] Step 3, 3-bromo-2-(1-ethoxyvinyl)-5-fluoro-aniline:

[0148] To a mixture of 3-bromo-5-fluoro-2-iodo-aniline (7.0 g, 22.2 mmol, 1.0 equiv) and tributyl(1-ethoxyvinyl)stannane (8.8 g, 24.4 mmol, 1.1 equiv) in toluene (100 mL) was added Pd(PPh3)4 (2.6 g, 2.2 mmol, 0.1 equiv) at 20°C under N2. The mixture was stirred at 120°C for 16 hours under N2. The mixture was cooled to 20°C, then KF aqueous solution (100 mL) was added, and the mixture was stirred at 20°C for 4 hours. The aqueous phase was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine (2×20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (100:1 to 20:1 petroleum ether:ethyl acetate) to give the title compound (4.2 g, 73% yield) as a yellow solid. LCMS [M-1] = 258.0. 1 H NMR (400 MHz, CHLOROFORM-d) δ 6.71 (dd, J = 2.4, 8.3 Hz, 1H), 6.35 (dd, J = 2.4, 10.4 Hz, 1H), 4.56 (d, J = 2.2 Hz, 1H), 4.29 (d, J = 2.2 Hz, 1H), 4.18 (brs, 2H), 3.91 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.0 Hz, 3H).

[0149] Step 4, 1-(2-amino-6-bromo-4-fluoro-phenyl)ethanone:

[0150] To a mixture of 3-bromo-2-(1-ethoxyvinyl)-5-fluoro-aniline (4.2 g, 16.2 mmol, 1.0 equiv) in acetic acid (72 mL) was added H2O (8 mL) at once at 20°C under N2. The mixture was stirred at 20°C for 10 hours. The mixture was concentrated under reduced pressure and then saturated aqueous NaHCO3 (200 mL) was added. The aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (99:1 to 20:1 petroleum ether: ethyl acetate) to give the title compound (1.9 g, 51% yield) as a yellow solid. LCMS[M-1]=229.9. 1 H NMR (400 MHz, CHLOROFORM-d) δ 6.71 (dd, J=2.4, 8.2 Hz, 1H), 6.34 (dd, J=2.4, 10.4 Hz, 1H), 4.89 (br s, 2H), 2.66 (s, 3H).

[0151] Step 5, 1-[2-amino-6-[(4-chlorophenyl)methyl]-4-fluoro-phenyl]ethylene ketone:

[0152] To a mixture of 1-(2-amino-6-bromo-4-fluoro-phenyl)ethanone (1.0 g, 4.3 mmol, 1.0 equiv), K3PO4 (1.8 g, 8.6 mmol, 2.0 equiv) and 2-[(4-chlorophenyl)methyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.3 g, 5.2 mmol, 1.2 equiv) in ethanol (8 mL) / H2O (2 mL) was added [2-(2-aminophenyl)phenyl]-methylsulfonyloxy-palladium; di-tert-butyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (342 mg, 431 μmol, 0.1 equiv) at 20°C under N2. The mixture was stirred at 80°C for 16 hours under N2. The mixture was cooled to 20°C and filtered through a pad of celite. The filtrate was poured into water (200 mL) and the aqueous phase was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (25 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50:1 to 20:1 petroleum ether:ethyl acetate) to give the title compound (274 mg, 23% yield) as a yellow oil. LCMS [M+1] = 278.0. 1H NMR (400 MHz, CHLOROFORM-d) δ 7.29-7.24 (m, 2H), 7.05 (d, J=8.4 Hz, 2H), 6.30 (dd, J=2.4, 10.2 Hz, 1H), 6.20 (dd, J=2.4, 9.6 Hz, 1H), 4.59 (br s, 2H), 3.98 (s, 2H), 2.40 (s, 3H).

[0153] Step 6, N-[2-acetyl-3-[(4-chlorophenyl)methyl]-5-fluoro-phenyl]-5-cyano-2-methylsulfanyl- Benzamide:

[0154] A mixture of 1-[2-amino-6-[(4-chlorophenyl)methyl]-4-fluorophenyl]ethanone (220 mg, 792 μmol, 1.0 equiv) and 5-cyano-2-methylsulfanyl-benzoyl chloride (184 mg, 871 μmol, 1.1 equiv) in isopropyl acetate (1 mL) was stirred at 80°C for 16 hours. The mixture was cooled to 20°C and then concentrated under reduced pressure. H2O (10 mL) was added to the residue and the mixture was stirred at 20°C for 10 minutes. The precipitate was filtered off in vacuo. The crude product was triturated with acetonitrile at 20°C for 30 minutes to give the title compound (260 mg, 73% yield) as a white solid. LCMS [M+1] = 453.1. 1 H NMR (400MHz, chloroform-d) δ9.29 (s, 1H), 8.02 (dd, J=2.4, 10.4Hz, 1H), 7.82 (d, J=1.8Hz, 1H), 7.70 (dd, J=1.8, 8.4Hz, 1H), 7.39 (d, J=8.4Hz, 1H), 7.33-7.28 (m, 2H), 7.05 (d, J=8.4Hz, 2H), 6.70 (dd, J=2.4, 8.8Hz, 1H), 4.09 (s, 2H), 2.55 (s, 3H), 2.48 (s, 3H).

[0155] Step 7, 3-[5-[(4-chlorophenyl)methyl]-7-fluoro-4-oxo-1H-quinolin-2-yl]-4-methylsulfanyl-benzene Formonitrile:

[0156] To a mixture of N-[2-acetyl-3-[(4-chlorophenyl)methyl]-5-fluorophenyl]-5-cyano-2-methylsulfanyl-benzamide (250 mg, 552 μmol, 1.0 equiv) in dioxane (3 mL) was added LiOH (14.5 mg, 607 μmol, 1.1 equiv) at 20°C under N2. The mixture was stirred at 110°C for 5 hours. The mixture was cooled to 20°C and then diluted with H2O (20 mL). The pH value of the mixture was adjusted to pH = 4-5 with 1N HCl aqueous solution. The formed precipitate was filtered off and washed with water. The crude solid was triturated with acetonitrile for 1 hour to give the title compound (200 mg, 83% yield) as a white solid. LCMS [M+1] = 435.1. 1 H NMR (400MHz, methanol-d4) δ7.83 (dd, J=1.6, 8.4Hz, 1H), 7.77 (d, J=1.8Hz, 1H), 7.57 (d, J=8.4Hz, 1H), 7.27-7.22 (m, 2H), 7.22-7.17 (m, 2H), 7.14 (dd, J=2.6, 9.2Hz, 1H), 6.92 (dd, J=2.4, 9.8Hz, 1H), 6.18 (s, 1H), 4.80 (s, 2H), 2.54 (s, 3H).

[0157] Step 8, 3-[5-[(4-chlorophenyl)methyl]-7-fluoro-4-oxo-1H-quinolin-2-yl]-4-methylsulfonyl-benzene Formonitrile:

[0158] To a mixture of 3-[5-[(4-chlorophenyl)methyl]-7-fluoro-4-oxo-1H-quinolin-2-yl]-4-methylsulfanyl-benzonitrile (100 mg, 230 μmol, 1.0 equiv) in acetone (1.4 mL) / H2O (0.8 mL) / THF (1 mL) / MeOH (1 mL) was added Oxone (424 mg, 690 μmol, 3.0 equiv) at room temperature under N2. The mixture was stirred at 50°C for 16 hours. The mixture was cooled to room temperature and then saturated Na2SO3 aqueous solution (3 mL) was added. The resulting mixture was stirred at room temperature for 10 minutes. The aqueous phase was extracted with ethyl acetate (50 mL). The organic layer was washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 75 x 30 mm x 3 um; mobile phase: [35-65% acetonitrile in water (+ formic acid)] to give the title compound (28 mg, 26% yield) as a white solid.

[0159] LCMS [M+1] = 467.0. 1H NMR (400 MHz, methanol-d4) δ 8.36 (d, J = 8.2 Hz, 1H), 8.19 (dd, J = 1.6, 8.2 Hz, 1H), 8.14-8.08 (m, 1H), 7.28-7.23 (m, 2H), 7.23-7.17 (m, 2H), 7.09 (dd, J = 2.4, 9.2 Hz, 1H), 6.92 (dd, J = 2.0, 9.6 Hz, 1H), 6.21 (s, 1H), 4.81 (s, 2H), 3.17 (s, 3H).

[0160] Biochemical and cellular assays

[0161] PPARγ-NCOR1 recruitment assay:

[0162] Compound potency (EC) was assessed by a TR-FRET binding assay measuring the association of a biotinylated NCOR1 ID2 peptide (biotin-GHSFADPASNLGLEDIIRKALMG-amide) with the PPARG / RXRA LBD heterodimer. 50 ) and NCOR1 were recruited to the maximum extent of PPARG. Specifically, 20 μL of TR-FRET master mix (composed of 2 nM WT PPARG LBD (E. coli expressed, His-TEV-Q203-Y477; Uniprot ID P37231-2), 2 nM WT RXRA LBD or mutant S427F RXRA LBD (E. coli expressed, F1ag-TEV-E228-T462; P19793-1), 50 nM NCOR1, 80 nM rosiglitazone, 25 nM streptavidin-d2 (Cisbio), and 0.3 nM anti-histidine Tb (Cisbio) in 25 mM MOPS pH 7.4, 25 mM KCl, 1 mM EDTA, 0.01% BSA, 0.01% Tween-20, and 1 mM TCEP) was added to a 384-well plate containing duplicate 60 nL of TR-FRET master mix. Compounds were titrated in a 10-point dose response in DMSO (0.3% fcDMSO (v / v)). The mixtures were incubated for 3 hours and read in an EnVision plate reader (Perkin Elmer) equipped with Ex / Em 615 / 665. To determine potency (EC 50 ) and the extent of NCOR1 recruitment, TR-FRET ratios were normalized to the average ratio of DMSO control wells (0%) and the average maximum ratio of the positive control compound (T0070907 (2-chloro-5-nitro-N-4-pyridinyl-benzamide); defined as 100%) in CDD Vault and analyzed using the Levenberg-Marquardt algorithm.

[0163] PPARγ-MED1 blocking assay:

[0164] Compound potency (IC) was assessed by a TR-FRET binding assay measuring the association of a biotinylated MED1 LxxLL peptide (biotin-VSSMAGNTKNHPMLMNLLKDNPAQ-amide) with the PPARG / RXRA LBD heterodimer. 50 Specifically, 20 μL of TR-FRET master mix (composed of 2 nM WT PPARG LBD (E. coli expressed, His-TEV-Q203-Y477; Uniprot ID P37231-2), 2 nM WT RXRA LBD (E. coli expressed, Flag-TEV-E228-T462; P19793-1), 350 nM NCOR1, 80 nM rosiglitazone, 175 nM streptavidin-d2 (Cisbio), and 0.3 nM anti-histidine Tb (Cisbio) in 25 mM MOPS pH 7.4, 25 mM KCl, 1 mM EDTA, 0.01% BSA, 0.01% Tween-20, and 1 mM TCEP) was added to a 384-well plate containing duplicate 60 nL Compounds were titrated in a 10-point dose response in DMSO (0.3% DMSO f.c. (v / v)). The mixtures were incubated for 3 hours and read in an EnVision plate reader (Perkin Elmer) equipped with Ex / Em 615 / 665. To determine potency (IC 50 ) and the extent of MED1 exclusion, TR-FRET ratios were normalized to the average ratio of DMSO control wells (0%) and the average minimum ratio of the positive control compound (GW9662 (2-chloro-5-nitrobenzanilide); defined as 100%) in CDD Vault and analyzed using the Levenberg-Marquardt algorithm.

[0165] Pharmacodynamics of Bladder Cancer

[0166] 5637 (PPARG amplification) and HT1197 (RXRA S427F mutation) cells were used to assess the regulation of PPARG target genes using quantitative PCR. Cells were treated with PPARG inverse agonists for 24 hours prior to analysis of FABP4 (IDT, catalog number: Hs.PT58.20106818) and ANGPTL4 (IDT, catalog number: Hs.PT58.25480012) expression, where expression across samples was normalized using expression of the housekeeping gene TBP (IDT, catalog number: Hs.PT 58v.39858774). Quantitative PCR was performed using the ABI QuantStudio 7FlexReaction system. Data were analyzed and reported relative to DMSO controls using the comparative Ct method (ΔΔCt).

[0167] Table 1

[0168] For the PPARG-NCOR recruitment assay, EC 50 The values ​​are indicated as follows, A: <10 nM, B: 10-100 nM, C: 100-1,000 nM, D: 1,000-10,000 nM, E: >10,000 nM. % NCOR recruitment is indicated as follows, A: >100% (>control compound, T907), B: <100% (<control compound, T907).

[0169] For the PPARG-MED1 recruitment assay, EC 50 The values ​​are indicated as follows, A: <10 nM, B: 10-100 nM, C: 100-1,000 nM, D: 1,000-10,000 nM, E: >10,000 nM. The % MED1 blocking is indicated as follows, A: >100% (>control compound, GW9662), B: <100% (<control compound, GW9662).

[0170] For HT1197 cell assays, EC 50 Indicated as follows, A: <10 nM, B: 10-100 nM, C: 100-1,000 nM, D: 1,000-10,000 nM, E: >10,000 nM, ND: not determined. % inhibition of ANGPTL4 (a PPARG target gene) at 100 nM compound concentration is expressed as a percentage of DMSO control experiments.

[0171]

[0172] Although we have described many embodiments, it is apparent that our basic examples can be altered to provide other embodiments utilizing the compounds and methods of the present invention. It should be understood, therefore, that the scope of the invention is defined by the appended claims rather than by the specific embodiments presented by way of example.

[0173] The contents of all references (including literature references, issued patents, issued patent applications and co-pending patent applications) cited in this application are hereby expressly incorporated herein in their entirety by reference. Unless otherwise defined, all technical and scientific terms used herein are consistent with the meanings commonly known to those of ordinary skill in the art.

Claims

1. A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: X, Y and Z are each independently selected from N and -CR 4 ; W is selected from O and CR a R b ; R 1 is selected from hydrogen, halogen, (C1-C4)alkyl and hydroxy; R 2 Selected from halogen, -SR a 、-SOR a 、-SO2R 2 、-OR a and -SO(=NR a )R b ; R 3 is selected from cyano and nitro; R 4 is selected from hydrogen, halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy and hydroxy; R 5 is selected from phenyl, heterocyclyl and heteroaryl, each of which is optionally substituted by 1 to 3 selected from R 8 The group substitution; R 6 and R 7 Each is independently selected from halogen, (C1-C4) alkyl, (C1-C4) alkoxy, halo (C1-C4) alkyl, halo (C1-C4) alkoxy, cyano, oxo, -(C1-C4) alkyl, OR a 、-(C1-C4)alkylC(O)R a 、-(C1-C4)alkylC(O)OR a 、-C(O)NR a R b 、-(C1-C4)alkylC(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-NR a R b 、-(C1-C4)alkylNR a R b 、-C(O)NR a SO3H, -NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(S)OR b 、-NR c C(O)N a R b 、-NR c C(S)NR a R b 、-NR c S(O)2NR a R b 、-C(S)R a 、-S(O)2R a 、-S(O)R a 、-C(S)OR a 、-C(S)NR a R b 、-NR a C(S)R b 、-SR a , phenyl, heterocyclic group and heteroaryl, wherein the phenyl, heterocyclic group and heteroaryl are each optionally and independently substituted by 1 to 3 selected from R 9 The group substitution; R 8 and R 9 Each is independently selected from halogen, (C1-C4) alkyl, halo (C1-C4) alkyl, (C1-C4) alkoxy, halo (C1-C4) alkoxy, nitro, oxo, cyano, -(C1-C4) alkyl, OR d 、-(C1-C4)alkylC(O)R d 、-(C1-C4)alkylC(O)OR d 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、-C(O)R d 、-C(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d SO3H, -NR d C(O)R e 、-NR d C(S)R e 、-NR d C(S)R e 、-NRfC(O)N d R e 、-NR f C(S)NR d R e 、-NR f S(O)2NR d R e 、-C(S)R d 、-S(O)2R d 、-S(O)R d 、-C(S)OR d 、-C(S)NR d R e 、-NR d C(S)R e and-SR d ; R a , R b , R c , R d and R e are each independently selected from hydrogen, (C1-C4)alkyl and halo(C1-C4)alkyl; and q and r are each independently 0 or 1.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 It's hydrogen.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein X, Y and Z are each -CR 4 .

4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R 4 is selected from hydrogen, (C1-C4)alkyl, halogenated (C1-C4)alkyl and (C1-C4)alkoxy.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 4 It's hydrogen.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein R 3 It's cyano.

7. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 6, wherein R 2 Selected from halogen, -SR a 、-SOR a 、-SO2R a and -SO(=NR a )R b .

8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R 2 Selected from halogen and -SO2R a .

9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein R 2 Selected from chlorine and -SO2Me.

10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein R 6 is selected from halogen, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, -(C1-C4)alkyl, OR d 、-(C1-C4)alkylC(O)ODd、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、-C(O)R d 、-C(O)OR d 、-S(O)2R d 、-S(O)R d and-SR d .

11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein r is 0.

12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein q is 1.

13. A compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from halogen, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, -(C1-C4)alkyl, OR d 、-(C1-C4)alkylC(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、C(O)R d 、C(O)OR d 、-S(O)2R d 、-S(O)R d and-SR d .

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein R 7 It's a halogen.

15. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 7 It's fluorine.

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein W is selected from O and CH2.

17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein W is O.

18. A compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, wherein R 5 selected from phenyl and monocyclic heteroaryl, each of which is optionally substituted by 1 to 3 selected from R 8 The group is substituted.

19. A compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof, wherein R 5 selected from phenyl and pyrazolyl, each of which is optionally substituted by 1 to 3 selected from R 8 The group is substituted.

20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 19, wherein R 8 is selected from halogen, oxo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, -(C1-C4)alkyl, OR d 、-(C1-C4)alkylC(O)OR d 、-NR d R e 、-(C1-C4)alkylNR d R e 、-C(O)NR d R e 、-(C1-C4)alkylC(O)NR d R e 、-C(O)R d 、-C(O)OR d 、-S(O)2R d 、-S(O)R d and-SR d .

21. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein R 8 Selected from halogen and (C1-C4)alkyl.

22. A compound as claimed in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein R 8 Selected from chlorine and methyl.

23. The compound of claim 1, wherein the compound is selected from: Or a pharmaceutically acceptable salt of any of the foregoing.

24. A pharmaceutical composition comprising the compound according to any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25. A method of treating a cancer responsive to inhibition of PPARG in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof.

26. The method of claim 25, wherein the cancer is selected from breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, kidney cancer, bladder cancer, testicular cancer, urothelial cancer, skin cancer, melanoma, colon cancer, kidney cancer, brain cancer, and hematopoietic cancer.

27. The method of claim 25 or 26, wherein the cancer is bladder cancer.